OVERVIEW
Stocktwits Top 25 Week 17
Welcome to the Stocktwits Top 25 Newsletter for Week 17 of 2024!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.
Here are the Stocktwits Top 25 Lists for Week 17:
P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
S&P 500
ST Top 25 S&P 500
The S&P 500 Top 25 list (+7.53%) outperformed the S&P 500 index (+2.67%).
There were 8 major changes to the list this week.
Check out how the momentum meter has performed vs. the S&P 500 index.
STOCKTWITS EDGE
Elevate Your Trading Game 👀
Unleash your trading potential with our new Edge subscription plan—featuring unique social data, an ad-free experience, and more!
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list (+6.34%) outperformed the Nasdaq 100 index (+3.99%).
There were 4 major changes to the list this week.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list (+10.98%) outperformed the Russell 2000 index (+2.79%).
There were 4 major changes to the list this week.
Top Dawg Of The Week 🐶
The Top 25 lists' Top Dawg was Cullinan Therapeutics, which rallied 61.56%. 📈
The small-cap biotech company focuses on developing oncology therapies for cancer patients in the U.S. More broadly, the small and mid-cap biotech space remains in focus as investors look for the next “takeover target” big pharma will tap to grow their pipelines. 🕵️
There was no specific news about the stock this week. Instead, the momentum continued following the prior week's news of its strategic expansion into autoimmune diseases and an oversubscribed $280 million private placement. 📰
$CGEM is up 148.28% YTD.
Get In Touch
Follow our social channels for great, real-time content on Stocktwits and Twitter. And check out our YouTube channel for in-depth video content! 📲
Help us deliver the best content possible by completing this brief survey. 📝
Email me (Tom Bruni) your feedback; I’d love to hear from you. 📧
Want to sponsor this newsletter and reach hundreds of thousands of passionate investors and traders? Reach us here. 👍
Disclaimer: Content, news, research, tools, and securities symbols are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍
